Cerecor, which is developing a novel adjunct therapy for major depressive disorder, announced terms for its IPO on Tuesday.
The Baltimore, MD-based company plans to raise $27 million by offering 4.2 million shares at a price range of $6 to $7. At the midpoint of the proposed range, Cerecor would command a fully diluted market value of $58 million.
Cerecor, which was founded in 2011, plans to list on the Nasdaq under the symbol CERC. Cerecor initially filed confidentially on 12/20/2013. Maxim Group LLC is the sole bookrunner on the deal.
